Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Top Trends in Life Sciences Consulting: What to Expect

Aug 08, 2025

Introduction to Life Sciences Consulting Trends

The life sciences sector is in a state of constant evolution, driven by advances in technology, regulatory changes, and the increasing demand for personalized medicine. As a result, life sciences consulting firms are adapting to these changes by embracing new trends and strategies. In this blog post, we will explore some of the top trends shaping the future of life sciences consulting.

Emphasis on Digital Transformation

One of the most significant trends in life sciences consulting is the growing emphasis on digital transformation. Companies are increasingly adopting digital technologies to enhance their research and development processes, improve patient engagement, and streamline operations. This trend is not just about implementing new technologies but also about transforming business models to deliver better outcomes.

Consultants are playing a crucial role in guiding life sciences companies through their digital transformation journeys. They help identify appropriate technologies, ensure seamless integration into existing systems, and develop strategies for effective implementation. Digital transformation is becoming a key driver of competitive advantage in the industry.

digital transformation

Personalized Medicine and Precision Health

The shift towards personalized medicine and precision health is another major trend impacting the life sciences sector. Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, while precision health focuses on disease prevention and health promotion through personalized approaches.

Life sciences consultants are instrumental in helping organizations navigate this complex landscape. They assist in developing personalized treatment plans, leveraging big data analytics to identify patient-specific insights, and managing regulatory challenges associated with personalized therapies. As personalized medicine continues to grow, so too will the demand for specialized consulting expertise.

personalized medicine

Regulatory Compliance and Risk Management

With the life sciences industry being highly regulated, maintaining compliance and managing risks are perpetual challenges. The regulatory environment is becoming more complex, with new guidelines and standards being introduced regularly. Life sciences consulting firms are stepping up to help companies stay compliant while minimizing risks.

Consultants provide valuable insights into regulatory requirements, assist in developing risk management frameworks, and support companies in navigating audits and inspections. By ensuring compliance and mitigating risks, consultants enable life sciences companies to focus on innovation and growth.

Sustainability and Ethical Considerations

Sustainability and ethical considerations are becoming increasingly important in the life sciences sector. With growing awareness of environmental issues and the need for socially responsible practices, companies are looking to integrate sustainable practices into their operations.

Life sciences consultants advise on sustainable practices, from reducing carbon footprints to ensuring ethical sourcing of materials. They help organizations develop sustainability strategies that align with industry standards and consumer expectations. This trend highlights the shift towards a more responsible and transparent approach within the industry.

sustainability

Collaboration and Open Innovation

Collaboration is vital in the life sciences sector as companies seek to leverage external expertise and resources. Open innovation models are becoming more prevalent, allowing organizations to collaborate with external partners such as academic institutions, research organizations, and other industry players.

Consultants facilitate these collaborations by identifying potential partners, managing intellectual property concerns, and ensuring that partnerships align with strategic goals. By fostering a culture of open innovation, life sciences companies can accelerate their research efforts and bring new treatments to market more efficiently.

Conclusion: The Future of Life Sciences Consulting

The life sciences sector is poised for significant transformation, driven by technological advancements, changing patient needs, and regulatory shifts. Life sciences consulting firms are at the forefront of these changes, providing critical support to organizations navigating this dynamic landscape.

Adapting to these trends will not only be essential for survival but also for thriving in an increasingly competitive environment. As we look to the future, the role of life sciences consulting will continue to evolve, offering new opportunities for innovation and growth.

consulting trend